Journal
SEMINARS IN THROMBOSIS AND HEMOSTASIS
Volume 43, Issue 2, Pages 191-199Publisher
THIEME MEDICAL PUBL INC
DOI: 10.1055/s-0036-1585077
Keywords
brain infarction; thromboembolism; fibrinolysis; blood-brain barrier; survival
Categories
Funding
- National Institute of Neurological Diseases and Stroke [NS089707]
- American Heart Association [GRBT3870005]
Ask authors/readers for more resources
Thrombotic vascular occlusion is the leading cause of ischemic stroke. High blood levels of (2)-antiplasmin (a2AP), an ultrafast, covalent inhibitor of plasmin, have been linked in humans to increased risk of ischemic stroke and failure of tissue plasminogen activator (tPA) therapy. Consistent with these observations, a2AP neutralizes the therapeutic benefit of tPA therapy in experimental stroke. In addition, a2AP has deleterious, dose-related effects on ischemic brain injury in the absence of therapy. Experimental therapeutic inactivation of a2AP markedly reduces microvascular thrombosis, ischemic brain injury, brain swelling, brain hemorrhage, and death after thromboembolic stroke. These data provide new insights into the critical importance of a2AP in the pathogenesis of ischemic brain injury and suggest that transiently inactivating a2AP may have therapeutic value in ischemic stroke.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available